Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000294157 is an antisense transcript overlapping the sense strand of the biotinidase (BTD) gene. Antisense transcripts are a class of non-coding RNAs transcribed from the opposite DNA strand of a protein-coding gene; they can modulate the expression of their corresponding sense gene by mechanisms such as chromatin remodeling, transcriptional interference, RNA masking, and double-stranded RNA-mediated pathways. The biological role of any specific antisense transcript is often undiscovered and context dependent; there is currently no evidence that "novel transcript, antisense to BTD" serves as a therapeutic target, biomarker, or has a direct role in disease. Such transcripts may contribute to gene regulatory networks, possibly affecting the expression or stability of the biotinidase gene product, but there are no established clinical or pharmacological applications for this transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript antisense to biotinidase (ENSG00000294157).